Keenova Therapeutics plc — Revenue by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/752c4014-60c5-49a2-8db7-5ee87f683773/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $1.4B | 2024-12-28 – 2025-12-31 | evidence 0001628280-26-025238 |
| FY 2024 | $1.1B | 2023-12-30 – 2024-12-27 | evidence 0001628280-26-025238 |
| FY 2023 | $949.2M | 2022-12-31 – 2023-11-14 | evidence 0001628280-26-025238 |
| FY 2021 | $2.2B | 2020-12-26 – 2021-12-31 | evidence 0001567892-22-000007 |
| FY 2020 | $2.2B | 2019-12-28 – 2020-12-25 | evidence 0001567892-21-000011 |
| FY 2019 | $3.2B | 2018-12-29 – 2019-12-27 | evidence 0001567892-20-000005 |
| FY 2018 | $3.2B | 2017-12-30 – 2018-12-28 | evidence 0001567892-19-000009 |
| FY 2017 | $3.2B | 2016-12-31 – 2017-12-29 | evidence 0001567892-19-000009 |
| FY 2016 | $3.4B | 2015-09-26 – 2016-09-30 | evidence 0001567892-19-000009 |
| FY 2015 | $2.9B | 2014-09-27 – 2015-09-25 | evidence 0001567892-16-000098 |
| FY 2014 | $1.7B | 2013-09-28 – 2014-09-26 | evidence 0001567892-16-000098 |
| FY 2013 | $1.7B | 2012-09-29 – 2013-09-27 | evidence 0001567892-15-000047 |
| FY 2012 | $2.1B | 2011-10-01 – 2012-09-28 | evidence 0001567892-13-000029 |
| FY 2011 | $2.0B | 2010-09-25 – 2011-09-30 | evidence 0001567892-13-000029 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Keenova Therapeutics plc — all facts · Net Income · Operating Income